Search
Bintrafusp alfa
go.drugbank.com/drugs/DB15387InvestigationalBintrafusp alfa is under investigation in clinical trial NCT03833661 (M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer
Perampanel
go.drugbank.com/drugs/DB08883ApprovedInvestigationalPerampanel is a noncompetitive AMPA glutamate receptor antagonist. … It is marketed under the name Fycompa™ and is indicated as an adjunct in patients over 12 years old for the treatment of partial-onset seizures that may or may not occur with generalized seizures.
Fexinidazole
go.drugbank.com/drugs/DB12265Approved[A237555, A237560] Fexinidazole received a positive opinion from the European Medicines Agency (EMA) in November 2018 and was approved by the FDA on July 16, 2021. … Transmitted by the bite of an infected tsetse fly, HAT is biphasic with a first (hemolymphatic) stage that progresses to a second (meningoencephalitic) stage in which patients experience progressively
Besilesomab
go.drugbank.com/drugs/DB13979ApprovedUtilised only as a diagnostic agent, besilesomab is currently approved by the EMEA for marketing and use in various European countries like Italy, France, Germany, Spain, Portugal, Norway, Sweden, the … Besilesomab is a mouse monoclonal antibody labelled with the radioactive isotope technetium-99m for determining the location of inflammation/infection in peripheral bone in adults with suspected osteomyelitis
Azatadine
go.drugbank.com/drugs/DB00719ApprovedWithdrawnAntihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells.
Mixtures: AFRINEX HAFexofenadine
go.drugbank.com/drugs/DB00950ApprovedInvestigational[A1452] Fexofenadine is the major active metabolite of [terfenadine][A1495] and is administered as a racemic mixture in which both enantiomers display approximately equivalent antihistamine activity. … Fexofenadine is an over-the-counter second-generation antihistamine used in the treatment of various allergic symptoms.
Iloperidone
go.drugbank.com/drugs/DB04946ApprovedInvestigational[A3024] It is considered to be a second-generation antipsychotic drug [A263552] with multiple receptor binding profile, although it shows high affinity towards 5-HT<sub>2A</sub> and dopamine D2 receptors … Iloperidone is a benzisoxazole [A263557] and an atypical antipsychotic agent that was first approved by the FDA on May 6, 2009.
Levoketoconazole
go.drugbank.com/drugs/DB05667ApprovedStill, toxicity has limited its use, notably hepatic toxicity and a tendency to prolong the QT interval.[A244083] Levoketoconazole is one of two enantiomers present in racemic [ketoconazole]. … changes in body composition, neuropsychiatric effects, changes in blood pressure and chemistry, and opportunistic infections.
Pentaerythritol tetranitrate
go.drugbank.com/drugs/DB06154ApprovedWithdrawnIt is recognized by the FDA to be a coronary vasodilator in the treatment of heart conditions such as angina [L2395]. … It is a pentaerythritol nitrate in which all four hydroxy groups of pentaerythritol have been converted to the corresponding nitrate ester.
Categories: Vasodilators Used in Cardiac DiseasesProducts: Peritrate Sa 80mg TabCaplacizumab
go.drugbank.com/drugs/DB06081ApprovedInvestigationalCaplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019,[L5302] and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression … [A174634]In December 2025, the FDA expanded this indication to include pediatric patients aged 12 years and older with aTTP, in the same combination regimen.[L54958,L54963]